Probiotics ameliorates LPS induced neuroinflammation injury on Aβ 1–42, APP, γ-β secretase and BDNF levels in maternal gut microbiota and fetal neurodevelopment processes

Kar, Fatih; Hacıoğlu, Ceyhan; Kar, Ezgi; Dönmez, Dilek Burukoğlu; Kanbak, Güngör

doi:10.1007/s11011-022-00964-z

Cited by 21 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, induction of APP indicates the potency of LPS to induce amyloidosis in our experimental system[61,62] This nding is in agreement with previous experiments where APP levels and amyloid aggregation were increased in the hippocampus and cerebral cortex of LPS-injected mice(Sheng et al 2003;Lee et al 2008Lee et al , 2012, and in LPS-treated astrocyte, microglia, and neuronal cultures(Lee et al 2008(Lee et al , 2012. Increased Αβ 1−42 and APP levels were also found in the brains of rat mothers and their offspring, as a result of LPS injection on the 17th day of pregnancy(Kar et al 2022). LPS also induced the expression of in ammatory and amyloidogenic factors, including β-and γ-secretases and brain-derived neurotrophic factor (BDNF), as well as the appearance of activated astrocytes(Qiao et al.…”

supporting

confidence: 92%

In vitro and in silico evaluation of the anti-amyloid and anti-inflammatory properties of curcumin and a V (IV) – curcumin complex in LPS-stimulated primary rat neurons-microglia mixed cultures

Katsipis

Lavrentiadou

Geromichalos

et al. 2023

Preprint

View full text Add to dashboard Cite

Lipopolysaccharides (LPS) of Gram-negative bacteria are mediators of neuroinflammation and neurodegeneration that have been detected in close association with aggregations of brain amyloid beta (Aβ) and microtubule-associated protein tau (MAPT). LPS induce the release of cytokines by microglia, the residing immune cells of the brain, and mediate the upregulation of inducible nitric oxide synthase (iNOS) – a mechanism associated with amyloidosis and MAPT destabilization. Curcumin is a natural product possessing several medicinal effects; however, its pharmaceutical exploitation is hindered by low bioavailability. V-Cur, a novel hemocompatible Vanadium (IV)-curcumin complex with higher solubility and pharmaceutical activity than curcumin, has been employed in the present study. Mixed cultures of primary rat brain neurons and microglia stimulated LPS presented increased levels of amyloid precursor protein (APP), an effect inhibited by either curcumin or V-Cur. V-Cur was also proved a more potent inhibitor of amyloid aggregation than curcumin, by both insulin aggregation assay and in silico studies. Cell stimulation with LPS increased full-length, inactivated, and total iNOS levels, and the inflammation markers IL-1β and TNF-α. Both curcumin and V-Cur alleviated these effects, with V-Cur reducing iNOS levels more than curcumin, whereas curcumin and V-Cur increased the MAPT levels in LPS-stimulated cells. Complementary insights into possible bioactivity mechanisms of both curcumin and V-Cur were provided by in silico molecular docking calculations on iNOS, TNF-α, IL-1β, Aβ1−42, APP and Aβ fibrils. This study renders curcumin-based compounds a promising anti-inflammatory intervention that may be proven a strong tool in the effort to mitigate neurodegenerative disease pathology and neuroinflammatory conditions.

show abstract

supporting

confidence: 92%

In vitro and in silico evaluation of the anti-amyloid and anti-inflammatory properties of curcumin and a V (IV) – curcumin complex in LPS-stimulated primary rat neurons-microglia mixed cultures

Katsipis

Lavrentiadou

Geromichalos

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Lactobacillus helveticus combined with Bifidobacterium longum have shown a decrease in hippocampal apoptosis in rats exposed to LPS 37 , as well as reducing serum cortisol -main stress hormone- levels in humans and rats 38 . Bifodobacterium bifidum and Lactobacillus salivarius administered in the prenatal period, decreased LPS and impacted foetal gut microbiota 39 . Cortisol has been found to influence the secretion of BDNF.…”

Section: Discussionmentioning

confidence: 95%

Effectiveness of a probiotic combination on the neurodevelopment of the very premature infant

Baucells,

Sebastiani,

Herrero-Aizpurua

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Probiotics have shown a benefit in reducing necrotising enterocolitis in the premature infant, however the study of their effect on premature neonates’ neurodevelopment is limited. The aim of our study was to elucidate whether the effect of Bifidobacterium bifidum NCDO 2203 combined with Lactobacillus acidophilus NCDO 1748 could positively impact the neurodevelopment of the preterm neonates. Quasi-experimental comparative study with a combined treatment of probiotics in premature infants < 32 weeks and < 1500 g birth weight, cared for at a level III neonatal unit. The probiotic combination was administered orally to neonates surviving beyond 7 days of life, until 34 weeks postmenstrual age or discharge. Globally, neurodevelopment was evaluated at 24 months corrected age. A total of 233 neonates were recruited, 109 in the probiotic group and 124 in the non-probiotic group. In those neonates receiving probiotics, there was a significant reduction in neurodevelopment impairment at 2 years of age RR 0.30 [0.16–0.58], and a reduction in the degree of impairment (normal-mild vs moderate-severe, RR 0.22 [0.07–0.73]). Additionally, there was a significant reduction in late-onset sepsis (RR 0.45 [0.21–0.99]). The prophylactic use of this probiotic combination contributed to improving neurodevelopmental outcome and reduced sepsis in neonates born at < 32 weeks and < 1500 g.Per style, a structured abstract is not allowed so we have changed the structured abstract to an unstructured abstract. Please check and confirm.Accepted

show abstract

“…In addition, activation of TLR4 due to changes in gut microbiota composition and gut permeability further leads to the release of pro-inflammatory cytokines, endotoxins (LSP) ( 67 ), etc., from astrocytes and from the microglia themselves. LPS may alter gut homeostasis, inflammation, and permeability ( 91 , 92 ) while activating various immune cells, including macrophages, neutrophils, and dendritic cells. Once activated ( 93 ), these cells produce a variety of pro-inflammatory cytokines, such as IL-2, IL-1β, IL-6, and TNF-α, which then cross the BBB into the brain via diffusion and cytokine transporters.…”

Section: Dysbiosis Of the Gut Microbiota In Als Affects The Gbamentioning

confidence: 99%

Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis

Zhang

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

There are trillions of different microorganisms in the human digestive system. These gut microbes are involved in the digestion of food and its conversion into the nutrients required by the body. In addition, the gut microbiota communicates with other parts of the body to maintain overall health. The connection between the gut microbiota and the brain is known as the gut–brain axis (GBA), and involves connections via the central nervous system (CNS), the enteric nervous system (ENS), and endocrine and immune pathways. The gut microbiota regulates the central nervous system bottom-up through the GBA, which has prompted researchers to pay considerable attention to the potential pathways by which the gut microbiota might play a role in the prevention and treatment of amyotrophic lateral sclerosis (ALS). Studies with animal models of ALS have shown that dysregulation of the gut ecology leads to dysregulation of brain–gut signaling. This, in turn, induces changes in the intestinal barrier, endotoxemia, and systemic inflammation, which contribute to the development of ALS. Through the use of antibiotics, probiotic supplementation, phage therapy, and other methods of inducing changes in the intestinal microbiota that can inhibit inflammation and delay neuronal degeneration, the clinical symptoms of ALS can be alleviated, and the progression of the disease can be delayed. Therefore, the gut microbiota may be a key target for effective management and treatment of ALS.

show abstract

Probiotics ameliorates LPS induced neuroinflammation injury on Aβ 1–42, APP, γ-β secretase and BDNF levels in maternal gut microbiota and fetal neurodevelopment processes

Cited by 21 publications

References 41 publications

In vitro and in silico evaluation of the anti-amyloid and anti-inflammatory properties of curcumin and a V (IV) – curcumin complex in LPS-stimulated primary rat neurons-microglia mixed cultures

In vitro and in silico evaluation of the anti-amyloid and anti-inflammatory properties of curcumin and a V (IV) – curcumin complex in LPS-stimulated primary rat neurons-microglia mixed cultures

Effectiveness of a probiotic combination on the neurodevelopment of the very premature infant

Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis

Contact Info

Product

Resources

About